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A B S T R A C T
Objectives: Marine ω-3 fatty acids (FAs) and Vitamin D (VitD) are reportedly capable of down-
regulating inﬂammation in rheumatoid arthritis (RA) and periodontal disease. This study was undertaken
to relate marine FA and VitD status to RA disease status and periodontal conditions.
Methods: RA outpatients (age ≥35 y) were consecutively recruited. Rheumatologic clinical data were col-
lected and periodontal status obtained. A food frequency questionnaire was used to estimate ﬁsh and
supplement intake. FA proﬁles in whole-blood and serum VitD levels were determined.
Results: A total of 78 RA patients (age 57 ± 12 y, disease duration 15 ± 11 y) were included, 58% had active
RA. Periodontitis was diagnosed in 82% of the patients, 18% had severe periodontitis. Seropositivity for
rheumatoid factor and/or anticitrullinated protein antibodies was related to higher prevalence of peri-
odontitis (P = 0.008). Seafood intake in accordance with nutritional recommendations was associated with
better RA disease outcome (largest P = 0.008). An ω-3 index >8, present in 14% of the patients, corre-
latedwith amore desirable patient global health assessment scored on a visual analog scale (VAS; P = 0.004),
lower periodontal probing depth (PD; P = 0.021), and ω-3 supplementation (P = 0.001). Serum VitD levels
>50 nmol/L were found in 89%, of these 48% had VitD levels ≥75 nmol/L, no differences were found for
RA disease activity and periodontal measurements.
Conclusions: Seropositive RA patients had a higher prevalence of periodontitis than seronegative pa-
tients. An ω-3 index >8 was related to ω-3 supplementation and more desirable VAS and lower PD. VitD
status was satisfactory for most patients and was not associated with differences in RA severity or peri-
odontal diagnosis.
© 2018 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Rheumatoid arthritis (RA) and periodontitis are chronic pro-
gressive inﬂammatory diseases associated with soft and hard
tissue destruction. Genetic, epigenetic, and environmental factors
drive host responses in both diseases [1–3]. An association
between periodontitis and RA has been described in systematic
reviews [4] and meta-analyses [5]. The etiopathogenesis of RA
is complex and the offending stimulus is still not clear. It is
hypothesized that a second inﬂammatory “hit” is required to stim-
ulate development of the disease [6]. Translocation and trapping
of oral bacterial DNA from inﬂamed periodontal tissue into sy-
novial ﬂuid suggest the involvement of periodontitis in the
etiopathogenesis of RA [7]. Although periodontal disease is clearly
initiated by bacteria, the underlying mechanisms are hyperac-
tive immune responses of the host to dysbiotic bacterial infection
[8]. Periodontitis is a major cause of tooth loss in adults, which
can exert a negative impact on nutritional status and health-
related quality of life (HRQOL) [9]. In active RA, systemic
inﬂammation is associated with multiple extraarticular
comorbidities such as depression, asthma, cardiovascular events,
malignancies, and chronic obstructive pulmonary disease, re-
sulting in a signiﬁcant reduction in HRQOL [10,11].
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Several studies have shown that fatty acid (FA) proﬁles of blood
lipids reﬂects dietary fat intake and relate to health status [12,13].
Polyunsaturated FAs (PUFAs) in the ω-3 series and ω-6 series are
precursors to potent lipid mediator signaling molecules, which
have important roles in immune regulation and inﬂammation [14].
Marine ω-3 PUFAs are capable of down-regulating inﬂamma-
tion in RA and periodontitis [15,16]. In most populations, intake
of ω-6 PUFA is increased, whereas the consumption of ω-3 PUFA
is either insuﬃcient or not effective at providing adequate tissue
levels of the ω-3 PUFA eicosapentaenoic acid (EPA) and
docosahexaenoic acid (DHA) [13].
Vitamin D (VitD) might affect RA and periodontal disease
through immunomodulatory effects. The active metabolite
1,25–dihydroxyvitamin D3 was found to downregulate pro-
inﬂammatory mediators such as TNF-α and RANKL in monocyte-
derived macrophages from peripheral blood of RA patients [17]
and to be inversely associated with severity of periodontitis in
non-RA patients [18]. In RA patients, serum 25-hydroxyvitamin
D (s-25[OH]D) levels were reduced and showed an inverse re-
lationship with RA disease activity, interleukin (IL)-17/IL-23, and
bone loss [19]. Whereas a higher VitD intake corresponded to
lower odds of severe periodontal disease, moderate-to-severe al-
veolar bone loss has been linked to lower VitD intake [20], and
insuﬃcient VitD status has been related to decreased clinical peri-
odontal attachment gain following periodontal surgery [21].
Genetic polymorphisms of the VitD receptor gene have also been
related to severity of RA and chronic periodontitis [22,23], and
enrichment of VitD response elements at RA-associated loci sup-
ports a role for VitD in development of this disease [24].
The aim of the present study was to examine the association
between RA disease status and periodontal conditions in rela-
tion to intake and status of marine ω-3 FA and VitD.
Methods
Ethics
Study protocol and informed written consent of all participants, according
to the Helsinki Declaration of 1975, version 2008 [25], were approved by the In-
stitutional Medical Research Ethics Committee (2012/2212), University of Bergen,
Norway.
Study design and patient selection
The data for this cross-sectional study were collected between May 2013 and
March 2016 at the Department of Rheumatology at Haukeland University Hos-
pital and at the Department of Clinical Dentistry at the University of Bergen
(Bergen, Norway). A patient ﬂow chart is presented in Figure 1. RA outpatients
with chronic established RA were invited to participate (N = 140). RA disease was
classiﬁed using the 2010 classiﬁcation criteria of American College of
Rheumatology/European League Against Rheumatism (ACR/EULAR) [26]. Inclu-
sion criteria were chronic established RA, Caucasian ethnicity, and ≥35 y of age.
Exclusion criteria were diabetes, malignancy, pregnancy, breast-feeding, and an-
tibiotic use within 3 mo before the study. Demographic and behavioral
characteristics were collected using questionnaires. Past medical history, clini-
cal, and laboratory data on RA status andmedication were obtained frommedical
records.
Assessment of RA disease activity
Recorded data included disease duration of RA, disease activity score (DAS28)
[27,28], joint damage, modiﬁed health assessment questionnaire (MHAQ) [29],
and a patient global health assessment scored on a visual analog scale (VAS).
Routine laboratory analyses included erythrocyte sedimentation rate (ESR),
C-reactive protein (CRP), rheumatoid factor (RF), and/or anticyclic citrullinated
peptides (anti-CCP) titers. Based on the laboratory reference level, all values >25 IU/
mL for RF and ≥3 U/mL for anticitrullinated protein antibodies (ACPAs) were
classiﬁed as seropositive for autoantibodies. VAS was measured on a horizontal
visual analog scale of 10 cm with “no pain” at one end and “worst possible pain”
at the other end. The patient was instructed to mark “X” on the scale by using
the following phrasing: “We kindly ask you to review the activity of your rheu-
matic disease during the last week. When you take all the symptoms into account,
how do you rate your condition?”. RA disease activity score (DAS28) was calcu-
lated using tender 28 joint score, swollen 28 joint score, ESR, and VAS. Active
RA was deﬁned as DAS28 ≥2.6 and remission as DAS28 <2.6 [30]. Low disease
activity was conﬁrmed if DAS28 score was ≤3.2, moderate if DAS28 score was
>3.2 to ≤5.1, and high if DAS28 score was >5.1 [31].
Disease modifying antirheumatic drugs (DMARDs) were grouped as follows:
Conventional DMARDs (methotrexate, leﬂunomide, hydroxychloroquine,
sulfasalazine), biological DMARDs (tumor necrosis factor [TNF]-inhibitors, B-cell
inhibitors, IL-6 inhibitors), and a combination of conventional and biological
DMARDs.
Clinical oral examination
Clinical oral examination and periodontal data collection were performed
under standardized conditions by a single dentist (K.B.). Detailed description is
provided in Supplementary Methods. Prior to the study, calibration training for
intraexaminer (K.B.) reproducibility of periodontal registrations was con-
ducted. The intraclass correlation coeﬃcient (ICC) ranged between 0.83 and 0.91
for probing depth (PD) and between 0.93 and 0.98 for clinical attachment level
(CAL).
A comprehensive periodontal examination including registration of PD, CAL,
bleeding on probing (BoP), and accumulation of bacterial plaque (plaque index,
PI) was assessed at six sites per tooth by using a manual periodontal probe (PCP-
26, Hu-Friedy, Chicago, Ilinois, USA). Thirdmolar, if not in position of secondmolar,
was excluded from periodontal registration.
Assessment of periodontal status
The periodontal status assessment was adapted from the Centers for Disease
Control-American Academy of Periodontology clinical case deﬁnitions with some
modiﬁcations [32]. Subjects were classiﬁed into three subgroups: 1) gingivitis:
PD ≤3mm, and BoP; 2) mild/moderate periodontitis: ≥ 2 interproximal sites with
CAL ≥3 mm (not on the same tooth) and ≥2 interproximal sites with PD ≥4 (not
on the same tooth) and BoP; or 3) severe periodontitis: ≥ 2 interproximal sites
with CAL ≥6mm (not on the same tooth) and ≥1 interproximal site with PD ≥5mm
and BoP.
Smoking status
Current smokers were deﬁned as subjects who smoked at the time of study
enrollment. Former smokers were subjects who had stopped smoking. The number
Not meeting inclusion criteria ( = 11)
Ethnicity ( = 3), Age < 35 years ( = 5),
Diabetes ( = 3)
Clinical medical examination
Clinical dental examination ( = 89)
Clinical data on RA and periodontal status
Questionnaires: FFQ
Laboratory analyses: PUFA, s-25(OH)D
Assessed for eligibility ( = 140)
Excluded ( = 51)
Declined participation ( = 26)
Discontinued (compliance) ( = 25)
Analyses ( = 78)
Fig. 1. Patient ﬂow chart. FFQ, food frequency questionnaire; PUFA, polyunsat-
urated fatty acid; RA, rheumatoid arthritis; s-25(OH)D, serum levels of 25-
hydroxyvitamin D.
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of pack-years was calculated by dividing the number of cigarettes smoked per
day by 20 and multiplying by the number of years smoked.
Assessment of seafood intake and dietary supplement intake
RA patients completed a validated, short version food frequency question-
naire (FFQ), described in detail by Dahl et al. [33]. In brief, semiquantitative and
retrospective habitual intake of seafood for dinner, as sandwich spread, in salads,
or as snack meal during the last three months was investigated. Additionally, self-
reported information about physical activity and sun exposure habits were
registered. The FFQ was analyzed as described by Markhus et al. [34]. To compute
the patients’ total seafood index, composed of the seafood dinner index, seafood
spread index, and ω-3 supplement index, the frequency data of the partici-
pants’ indices were converted into numerical values. Adaptions to Markhus et al.
[34] weremade regarding the frequencies for total dinner seafood index as follows:
“once a week” was converted to the numerical value 1, “two to three times per
week” set to value 2.5, and “four or more times per week” was set to value 4.
For the total seafood spread index, the frequencies were converted as follows:
“three to ﬁve times per week” was set to the numerical value 4 and “more than
ﬁve times per week” was set to value 5. The range of the total seafood index was
0 to 14. A standard Norwegian dinner seafood portion is deﬁned as 150 g (e.g.,
one slice of salmon ﬁllet, three ﬁshcakes, or 2 dL of shrimp) [35]. According to
the Norwegian food recommendations, 300 to 450 g/wk of ﬁsh for dinner and
spread (ﬁsh ﬁlet and processed ﬁsh products) should be part of a healthy bal-
anced diet, of which at least 200 g should be oily ﬁsh [36]. The total ﬁsh intake
per week (including ﬁsh ﬁlet, ﬁsh as spread, and processed ﬁsh) corresponds to
54 g/d of raw ﬁsh and 35 g/d for oily ﬁsh [37].
The FFQ also provided information about the use of supplements (marine
ω-3, VitD, and calcium) during the last 3mo. For ω-3 supplement, product names,
amount (capsules or spoons), and frequency of supplement intake were re-
corded. Seasonal variation in ω-3 supplement intake during the year was registered.
The questionnaire was designed to be self-instructive; however, assistance
was provided in case of item non-response.
Blood collection
Peripheral venous blood samples were obtained by venipuncture at the an-
tecubital fossa (Vacutainer Blood Collection Set, BD Vacutainer, Becton, Dickinson
and Company, Franklin Lakes, New Jersey).
Laboratory analyses
For analysis of s-25(OH)D levels, 4 mL venous blood was collected in Serum
Sep Clot Activator vacutainers (Greiner Bio-One Gmbh, Kremsmuenster, Austria)
and set to coagulate for minimum 30 min (maximum 60 min). After centrifuga-
tion at 1300 × g for 10 min, the supernatant was stored at −80°C until analysis.
S-25(OH)D was determined by isotope dilution liquid chromatography-tandem
mass spectrometry (LC-MS/MS) at the Hormone Laboratory at Haukeland Uni-
versity Hospital, Bergen, Norway [38]. S-25(OH)D levels were measured as sum
of ergocalciferol (25[OH]D2) and cholecalciferol (25[OH]D3), whereas 25(OH)D2
was found to be below the limit of quantiﬁcation (LOQ). VitD status was evalu-
ated as follows: Deﬁciency <20 ng/mL (<50 nmol/L), insuﬃciency 20 to 30 ng/
mL (50–75 nmol/L), and suﬃciency >30 ng/mL (>75 nmol/L) [39,40]; or deﬁciency
<12 ng/mL (<30 nmol/L), insuﬃciency 12 to 20 ng/mL (30–50 nmol/L), and suf-
ﬁciency >20 ng/mL [41].
Whole-blood samples for analysis of FA were collected in 3 mL EDTA
vacutainers (Greiner Bio-One Gmbh, Kremsmuenster, Austria) and analyzed at
Institute of Marine Research, Bergen, Norway, using ultrafast gas chromatogra-
phy (UFGC) as an accredited laboratory method (NS-EN ISO/IEC 17025). The FA
composition was calculated using an integrator (Chromeleon 6.80, Dionex Cor-
poration, California) connected to the UFGC. The limit of quantiﬁcation (LOQ) was
0.01, values <0.1 were recoded to the half of LOQ. Results were expressed as per-
centage of total FA by summing the absolute values of all analyzed FAs and dividing
each FA by this value.
Evaluation of ω-3 FA status
The ω-3 index was used to evaluate ω-3 FA status and is deﬁned as the sum
of EPA and DHA, expressed as percentage of total FA [42].
Statistical analyses
Median and range were calculated for continuous variables. The Shapiro-
Wilk test for normality was used to test for normality with a critical alpha value
of 5%. The Wilcoxon rank-sum test was applied for continuous variables not nor-
mally distributed. Student t test (for continuous variables) and Pearson chi-
square (for categorical variables) were used to test for differences between the
groups. For the site-speciﬁc measures of PD and CAL, taken at each site for all
teeth for each patient, mixed effect models with a random effect for patient and
tooth were performed. For the relation between RA disease activity and the site-
speciﬁc measures, logistic regression models with robust variance estimates
adjusting for the clustering of tooth within patients were performed. A P
value < 0.05 was considered statistically signiﬁcant. All statistical data analysis
was performed using the statistical software STATA version 14.0 for Microsoft
Windows (StataCorp LP, Texas).
Results
The study population consisted of 78 RA patients (58% with
active RA disease), ages 57 y (range 35.1–77.6 y). Categorical vari-
ables, behavioral and clinical characteristics, grouped by RA disease
activity, are summarized in Table 1. Continuous variables and clin-
ical characteristics, also grouped by RA disease activity, are
summarized in Table 2. A description of the study subjects by sex
is presented in Supplementary Tables S1 for categorical vari-
ables and Table S2 for continuous variables.
RA status
Active RAwith low, moderate, or high disease activity (DAS28)
was found in 23 (30%), 17 (22%), and 5 (6%) patients, respective-
ly. In relation to disease duration, DAS28 differed in neither active
RA nor remission (P = 0.51). Patients with active RA had
Table 1
Categorical variables and behavioral and clinical characteristics in RA patients,
grouped by disease activity (N = 78)
Remission
(N = 33)
Active RA
(N = 45)
P value
n (%) n (%)
Females 24 (73) 33 (73) 0.95
Smoking status
Never smokers 12 (36) 17 (38) 0.74
Former smokers 17 (52) 20 (44)
Current smokers 4 (12) 8 (18)
Periodontal conditions
Gingivitis 5 (15) 9 (20) 0.68
Mild/moderate periodontitis 23 (70) 27 (60)
Severe periodontitis 5 (15) 9 (20)
Medical data on RA disease
Seropositive 28 (85) 32 (71) 0.16
Seropositivity for IgM-RF 22 (67) 19 (42) 0.044
Seropositivity for ACPAs 26 (79) 29 (64) 0.11
Joint destruction 19 (58) 22 (49) 0.45
Antirheumatic medication 31 (94) 43 (96) 0.45
Conventional DMARDs 13 (39) 20 (44)
Biological DMARDs 7 (21) 4 (9)
Combination conventional and
biological DMARDs
11 (33) 19 (42)
Prednisolone 4 (12) 17 (38) 0.012
Other medication
Oral bisphosphonates 3 (9) 5 (11) 0.77
Folic acid 19 (58) 28 (62) 0.68
Calcium 10 (30) 22 (49) 0.10
Supplements
ω-3 17 (52) 26 (58) 0.58
Vitamin D 15 (45) 28 (62) 0.14
ACPA, anticitrullinated protein antibody; DAS28, disease activity score 28; DMARDs,
disease-modifying antirheumatic drugs; RA, rheumatoid arthritis; RF, rheuma-
toid factor.
Values reported as number and percentage of patients. RA disease activity, di-
agnosed by DAS28; seropositive, positive tests for RF (N = 74) and/or ACPA (N = 77).
Analyzed with Pearson chi-square.
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signiﬁcantly elevated clinical and laboratory parameters
related to RA disease than patients in remission (P < 0.001,
Table 2). Of note, 54% (N = 22) of the RF positive patients
and 30% (N = 10, P = 0.044) of the RF negative patients were in
RA disease remission. Prednisolone treatment (mean dose
7.4 μg/d, range 2.5–30), was found in a higher number of pa-
tients with active RA disease (N = 17, 38%) than in RA patients
with remission (N = 4, 12%; P = 0.012); no differences were found
for DMARDs.
Regarding the relation of smoking on RA disease activity, no
differences were found between active disease and remission
(P = 0.74; Table 1). In current smokers, the mean smoking pack-
years were 14 y (range 5–30 y). Differences in smoking status were
found in ACPA seropositive patients compared with seronega-
tive patients (P = 0.049). A higher proportion of ACPA seropositive
(N = 23, 42%) than seronegative patients (N = 6, 27%) were never
smokers and more seronegative patients were current smokers
(N = 7, 32%) compared with seropositive patients (N = 5, 9%;
P = 0.043). Smoking status did not differ in RF seropositive pa-
tients (P = 0.63).
Periodontal status
Gingivitis was diagnosed in 18%, mild to moderate periodon-
titis in 64%, and severe periodontitis in 18% of the patients.
Periodontal disease statusworsenedwith increased age (P = 0.008).
The mean ages of patients with gingivitis, mild to moderate, or
severe periodontitis were 51, 58, and 63 y, respectively. For the
severity of periodontal disease, signiﬁcant differences for PD
(P < 0.001), CAL (P < 0.001), BoP (largest P = 0.033), and PI (largest
P = 0.010) were found (Supplementary Table S3). Periodontitis was
found in a higher number of patients who tested seropositive for
RF and/or ACPA (N = 53, 88%) compared with seronegative pa-
tients (N = 11, 61%; P = 0.008).
At patient level for PD and CAL, respectively, a median (range)
of 3 mm (1–10 mm) and 3 mm (1–14 mm) was found. At tooth
level, mandibular molars had the highest mean PD (3.3 mm) and
mean CAL (3.6mm).Mandibular incisors (PD 2.4mm, CAL 2.7mm)
and premolars (PD 2.5mm, CAL 3.0mm) had a lower PD/CAL com-
pared with their respective maxillary teeth (PD 2.6 mm, CAL
2.8 mm; and PD 2.8 mm, CAL 3.2 mm, respectively). Compared
with mandibular incisors, all other tooth types in both jaws had
signiﬁcantly deeper PD (P < 0.001) and CAL (P < 0.001).
At site level, the majority of sites showed PD and CAL ≤3 mm
(90% and 83%, respectively). Sites with PD and CAL of 4 mmwere
found in 7% and 9.5%, and PD and CAL ≥5 mm were found in 3%
and 7.5%, respectively.
Dichotomizing study subjects by remission and active RA
disease (DAS28 <2.6 or DAS28 ≥2.6), no differences in PD, CAL,
BoP, PI at site level, or number of missing teeth were found
(highest P = 0.11). Patients diagnosed with active RA and peri-
odontitis (N = 36) had a higher mean CRP (12.9 ± 16.4) and ESR
(26.5 ± 18.0) compared with RA patients in remission having peri-
odontitis (N = 28; CRP 5.4 ± 10.8, P = 0.043 and ESR 12.6 ± 8.6,
P < 0.001). In patients without periodontitis, no differences were
found between active RA and remission for CRP (P = 0.13) and ESR
(P = 0.48).
Concerning the effect of smoking on PD and CAL, ever smokers
had higher mean PD (2.9 ± 0.4mm) andmean CAL (3.2 ± 0.9mm)
compared with never smokers (PD 2.6 ± 0.2 mm, P = 0.002 and
CAL 2.8 ± 0.3 mm, P = 0.015); no difference was found between
active RA and remission RA. With regard to sex, males who
were ever smokers had a higher mean PD (3.2 ± 0.6 mm) and
CAL (4.0 ± 1.4 mm) compared with females (PD 2.8 ± 0.1 mm,
P = 0.005 and CAL 2.9 ± 0.4 mm, P < 0.001). Moreover, male sex
and smoking were associated with higher prevalence and more
severe periodontitis (P = 0.037), fewer teeth (P < 0.001), and more
dental plaque (P = 0.017) compared with female sex in ever
smokers. Between former and current smokers, no differences
were found.
Food frequency questionnaire
All patients reported seafood consumption as dinner, and 96%
reported seafood as spread. The frequency of seafood intake as
dinner and as spread, the number of portions as dinner, and the
corresponding amount of seafood intake in grams per day are pre-
sented in Table 3.
The mean intake of seafood as dinner was 1.9 ± 0.9 meals per
week. The consumption of seafood as a spread, such as on a sand-
wich, in a salad, or as a snack, was 1.4 ± 1.4 meals per week. A
seafood intake as dinner with ≥2 to 3 servings per week and a
meal size corresponding to the standard Norwegian seafoodmeal
size or higher was found in 45 patients (58%). Of them, 27 (60%)
reported 1 to 2 weekly serving with oily ﬁsh as dinner. The rel-
ative amount of seafood meals as dinner per week was 38% oily
ﬁsh, 32% lean ﬁsh, 16% manufactured ﬁsh product, 5% interme-
diate oily ﬁsh and shellﬁsh each, and <5% fresh water ﬁsh and
sushi.
Regarding RA disease severity, females consuming two ormore
ﬁsh meals per week (N = 33) were found to have lower mean
MHAQ (0.26) and VAS (22.6) compared with females having a
lower ﬁsh intake (N = 24, MHAQ 0.51, P = 0.008 and VAS 38.4,
P = 0.003). No differences were found in males (MHAQ: P = 0.59;
VAS: P = 0.22).
Table 2
Continuous variables, clinical characteristics of all rheumatoid arthritis pa-
tients and grouped by disease activity (N = 78)
Total Remission Active RA P value
N = 78 N = 35 N = 43
Age (y) 57.1 ± 11.5 56.5 ± 11.6 57.5 ± 11.6 0.70
BMI (kg/m2) 26.1 ± 4.3 25.9 ± 4.4 26.3 ± 4.4 0.63*
Oral data
Teeth, n 25 ± 5 25 ± 4 24 ± 6 0.22
PD (mm) 2.8 ± 0.4 2.7 ± 0.3 2.8 ± 0.4 0.65
CAL (mm) 3.1 ± 0.8 3.0 ± 0.7 3.1 ± 0.8 0.57
BoP (% of sites) 31 ± 16 33 ± 14 30 ± 17 0.49
PI (% of sites) 33 ± 16 36 ± 19 31 ± 14 0.20
RA data
RA debut (age) 43 ± 14 41 ± 13 45 ± 15 0.30
RA duration (y) 15 ± 11 16 ± 12 14 ± 11 0.37*
DAS28 (score) 3.0 ± 1.1 2.1 ± 0.3 3.7 ± 1.0 <0.001*
VAS (score) 28 ± 21 17 ± 14 36 ± 21 <0.001*
MHAQ (score) 0.37 ± 0.38 0.17 ± 0.25 0.52 ± 0.39 <0.001*
Laboratory data
ESR (mm/h) 19.8 ± 15.5 12.7 ± 8.3 25.0 ± 17.5 <0.001*
CRP (mg/L) 8.8 ± 13.5 5.0 ± 10.0 11.6 ± 15.1 0.001*
S- 25(OH)D (nmol/L) 74 ± 19 78 ± 19 71 ± 19 0.071
Supplementation
Vitamin D (μg/d)† 27 ± 12 30 ± 13 25 ± 12 0.25*
BMI, body mass index; BoP, bleeding on probing; CAL, clinical attachment level;
CRP, C-reactive protein; DAS28, disease activity score 28; ESR, erythrocyte sed-
imentation rate; MHAQ, modiﬁed health assessment questionnaire; PD, probing
depth; PI, plaque index; RA, rheumatoid arthritis; s-25(OH)D, 25-hydroxy vitamin
D; VAS, visual analog scale.
Values reported as mean ± standard deviation.
Analyzed with Student t test.
* Analyzed with Wilcoxon rank-sum.
† Vitamin D users only (N = 45).
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Elderly patients (N = 44, >60 y of age) had higher median total
seafood intake (64 ± 57 g/d, range 13–345) than younger pa-
tients (N = 34, ≤60 y of age, 43 ± 35 g/d, range 1–213; P = 0.009).
Fish consumption of ≥54 g/d for dinner was found in 31% of
the patients (89 ± 59 g/d, range 55–331). Between sex, ﬁsh con-
sumption ≥54 g/d for dinner was found in 53% of the males
(74 ± 16 g/d, range 57–107) and 23% of the females (102 ± 79 g/
d, range 55–331 g/d; P = 0.27), whereas ≥34 g/d oily ﬁsh for dinner
was consumed by 14% (43 ± 0 g/d, range 43–43) and 5%
(107 ± 37 g/d, range 64–129; P = 0.040) of males and females,
respectively.
Use of marine ω-3 supplement was reported by 43 patients
(55%); of them, 19 (44%) tookmarine ω-3 supplements only during
wintertime (mean 5.3 mo). The mean intake was 3.9 ± 2 times
per week. At the time of examination, 37 (86%) were using an
ω-3 supplement. No differences in use of marine ω-3 supple-
ments for RA disease status and periodontal conditions were
found.
Intake of cholecalciferol (VitD3) supplement from ω-3 and/
or calcium supplement was reported by 43 patients (Tables 1 and
2). VitD3 originating from ω-3 supplement (17 ± 6 μg/d) was reg-
istered in 32 patients (41%). The estimated intake of VitD3 from
calcium supplement was 20 ± 5 μg/d. No differences for high or
low ultraviolet light exposure regarding RA disease activity or
between sex were found.
VitD3 users had higher s-25(OH)D levels (78 ± 17 nmol/L) com-
pared with non-users (68 ± 20 nmol/L, P = 0.021). VitD3 users
having oily ﬁsh for dinner ≥1 to 2 times per week had higher
s-25(OH)D levels (80 ± 18 nmol/L) compared with VitD3 non-
users having less oily ﬁsh (63 ± 15 nmol/L, P = 0.009). A
s-25(OH)D < 50 nmol/L was found in females, only (N = 6,
42 ± 7 nmol/L), ﬁve of six were not using VitD3.
There were no differences for s-25(OH)D between remission
and active RA disease (Table 2), periodontal diagnosis (data not
shown), nor sex (supplementary Table S2).
FAs and ω-3 index
The relative weight percentage of selected whole blood FA in
all patients and grouped by RA disease activity are presented in
Table 4. Selected whole blood FA (wt%), grouped by sex, and ac-
cording to the use and no use of marine ω-3 supplement are
presented in Supplementary Table S4.
The mean ω-3 index was 6.2 ± 2.1 (range 3–12). The majori-
ty of the study population had an ω-3 index from 4 to ≤8, 14%
Table 3
Frequency, number of portions, and estimated intake of seafood in RA patients, and grouped by sex and RA disease activity (N = 78)
Total (N = 78) Females (N = 57) Males (N = 21) P value Remission (N = 33) Active RA (N = 45) P value
Seafood for dinner
Never 0 0 0 0 0
<1 time/mo 2 2 0 0.44 2 0 0.31
1 to 3 times/mo 3 1 2 2 1
1 time/wk 28 21 7 9 19
2 to 3 times/wk 43 32 11 19 24
≥4 times/wk 2 1 1 1 1
Portion size of dinner
≤0.5 portion 3 3 0 0.010 2 1 0.32
1 portion 45 38 7 22 23
1.5 portions 22 13 9 7 15
2 portions 8 3 5 2 6
3 portions 0 0 0 0 0
Seafood as spread
Never 3 3 0 2 1
<1 time/mo 13 9 4 0.71 6 7 0.91
1 to 3 times/mo 25 19 6 11 14
1 to 2 times/wk 24 16 8 10 14
3 to 5 times/wk 10 7 3 3 7
>5 times/wk 3 3 0 1 2
Seafood intake (g/d)
Total seafood 52 ± 47 50 ± 52 57 ± 29 0.067* 42 ± 30 60 ± 55 0.063*
Dinner seafood 47 ± 44 46 ± 49 53 ± 28 0.058* 37 ± 28 54 ± 53 0.045*
Oily ﬁsh 18 ± 22 18 ± 24 19 ± 15 0.23* 12 ± 11 22 ± 27 0.030*
Intermediate/lean ﬁsh 17 ± 20 18 ± 20 22 ± 18 0.24* 16 ± 15 21 ± 22 0.32*
RA, rheumatoid arthritis.
Values reported as number of patients and mean ± standard deviation. Portion size = 150 g.
Analyzed with Pearson chi-square.
* Analyzed with Wilcoxon rank-sum.
Table 4
Relative weight percentage of selectedwhole-blood FAs in RA patients and grouped
by disease activity (N = 78)
Weight percentage of FA (wt%)
Total Remission Active RA P value
N = 78 N = 35 N = 43
Saturated FA 37.5 ± 1.9 38.0 ± 2.1 37.3 ± 1.8 0.15
Unsaturated FA 20.6 ± 2.6 20.1 ± 2.1 20.9 ± 2.9 0.24*
Polyunsaturated FA 39.2 ± 2.5 39.2 ± 2.0 39.2 ± 2.8 0.99
Sum ω-6 FA 30.7 ± 2.5 30.7 ± 2.5 30.6 ± 2.5 0.94
Sum ω-3 FA 8.5 ± 2.3 8.5 ± 2.1 8.5 ± 2.4 0.92*
ω-3 index 6.2 ± 2.1 6.2 ± 2.0 6.2 ± 2.2 0.98*
LA, 18:2 ω-6 18.9 ± 2.1 18.9 ± 2.3 18.9 ± 1.9 0.74*
AA, 20:4 ω-6 9.3 ± 1.4 9.2 ± 1.3 9.3 ± 1.5 0.98
ALA, 18:3 ω-3 0.6 ± 0.2 0.6 ± 0.3 0.6 ± 0.2 0.74*
EPA, 20:5 ω-3 1.7 ± 1.1 1.7 ± 1.2 1.7 ± 1.1 0.96*
DPA, 22:5 ω-3 1.2 ± 0.2 1.3 ± 0.2 1.2 ± 0.2 0.08
DHA, 22:6 ω-3 4.5 ± 1.1 4.4 ± 0.9 4.4 ± 1.2 0.87*
AA, arachidonic acid; ALA, α-linolenic acid; DHA, docosahexaenoic acid; DPA,
docosapentaenoic acid; EPA, eicosapentaenoic acid; FA, fatty acid; LA, linolenic
acid; RA, rheumatoid arthritis; wt%, weight percentage of total FA.
Fatty acids (FAs) are reported as mean ± standard deviation in weight percent-
age (wt%) calculated from total FA (wt%). Limit of quantiﬁcation (LOQ) 0.1, values
<0.1 were recoded to the half of LOQ.
Analyzed with Student t test.
* Analyzed with Wilcoxon rank-sum.
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had an ω-3 index >8, and 12% had an ω-3 index <4. Older age (>60
y of age) was related to a higher ω-3 index (5.5 ± 1.8) compared
with younger age (≤60 y of age, 7.1 ± 2.1; P < 0.001). ω-3 supple-
ment users had a higher ω-3 index compared with non-users
(P < 0.001; Supplementary Table S3).
Fish consumption as dinner ≥2 to 3 times per weekwas related
to a higher ω-3 index (6.6 ± 2.0) compared with less ﬁsh con-
sumption (5.5 ± 2.1, P = 0.019). An additional increase of ω-3 index
was found in patients having oily ﬁsh ≥1 to 3 times per week
(7.1 ± 1.9, P = 0.018). Patients with an ω-3 index >8 were ω-3 sup-
plement users and 83% of them had ≥2 to 3 weekly seafood
servings as dinner.
Smoking was related to a lower ω-3 index in current and
former smokers (5.7) comparedwith never smokers (7.1, P = 0.003).
Former smokers had an ω-3 index of 0.03 higher than current
smokers (P = 0.96).
The relations of the different levels of ω-3 index to selected
FA, total seafood intake, periodontal conditions and RA disease
are presented in Table 5.
Discussion
This study investigated marine ω-3 and VitD levels, disease
outcome, and periodontal status in RA outpatients. Periodonti-
tis was more prevalent in RA patients seropositive for RF and/
or ACPA. The RA disease parameters MHAQ and VAS were lower
in females consuming seafood as recommended. The use of ω-3
supplement was associated with an ω-3 index >8.
In the present study, females were approximately three times
more preponderant and appeared at a younger age than males
when diagnosed with RA. Previous reports conﬁrm this ﬁnding,
describing a female dominance, especially in the premeno-
pausal age group. This relationship has been interpreted in terms
of both genetic and non-genetic risk factors [43].
Periodontitis was diagnosed in more than three-quarters of
the RA patients. Data from a meta-analysis have shown that RA
patients were more likely to have a higher prevalence and se-
verity of periodontitis than non-RA controls, and patients with
periodontitis had a higher prevalence of RA than those without
periodontitis [5]. The prevalence of periodontitis in our group
of RA patients was almost twice as high for moderate and severe
periodontitis compared with American non-RA adults (ages ≥30
y), using similar diagnostic criteria for periodontitis [44]. Com-
pared with an epidemiologic study on oral health of inhabitants
in Jönköping, a Swedish city, the prevalence of periodontitis in
RA patients in our study was 2.6 times higher, and twice as
many patients were diagnosed with severe periodontitis [45].
Importantly, the classiﬁcation systems applied were different
in the studies. Overall, in our study, applying the classiﬁcation
system by Eke et al. [32], severe periodontitis was found in a
slightly higher proportion than the commonly reported range
of 5% to 15% in any population [46]. Nevertheless, PD and CAL
≥4 mm were identiﬁed in only 10% and 17% of the sites, respec-
tively. The low number of sites with severe periodontitis and
narrow interindividual differences might be the reason why we
were not able to show differences for periodontal measure-
ments between active RA and remission.
Smoking and male sex have been reported as risk factors for
more severe periodontitis [44,46]. Accordingly, male smokers had
signiﬁcantly higher mean PD and CAL compared with their re-
spective counterparts. Furthermore, periodontitis worsened with
age, reﬂecting lifetime disease accumulation [46].
One of the strengths of this study is the performance of com-
prehensive periodontal measurements at site level including both
PD and CAL. Prevalence and severity estimates of periodontitis
depend on clinical assessment for periodontal measures and case
deﬁnitions used for periodontitis. The assessment of both PD and
CAL at six sites per tooth is the gold standard in clinical peri-
odontal examination to estimate the entire extent of periodontitis
[44]. As a limitation and similar to the majority of the pub-
lished studies, third molars were excluded to make our results
best comparable, but extent and severity of periodontitis may have
been underestimated [44].
Seropositivity to ACPA has been found to have a strong cor-
relation with RA disease severity [47] and is also associated with
a higher frequency of periodontitis compared with healthy con-
trols [5]. In the present study, patients seropositive to ACPA and/
or RF were signiﬁcantly more frequently diagnosed with
periodontitis.
Smoking is a major preventive risk factor for RA [48]. Espe-
cially in seropositive patients, smoking has been found positively
associated with the risk of RA [48,49]. In a Swedish population-
based case-control study, a dose-response association between
cumulative dose of smoking and risk of developing ACPA posi-
tive RA has been observed [50]. In our study, a higher proportion
of ACPA seropositive patients were non-smokers, and fewer pa-
tients were current smokers comparedwith seronegative patients.
The high number of never and former smokers in this study may
explain the inability to show signiﬁcant differences between
smoking status and RA disease activity.
Table 5
ω-3 index in relation to selected whole-blood FAs, total seafood intake, and clin-
ical parameters on periodontal conditions and RA (N = 78)
ω-3 index ω-3 index ω-3 index
<4 4 to ≤8 >8
N = 9 (12%) N = 58 (74%) N = 11 (14%)
Age (y) 48 ± 12 57 ± 11 64 ± 9
FAs (wt%)
ω-3 index 36 ± 0.3 5.9 ± 1.2 A 10.2 ± 1.1 B,C
Sum ω-6 FA 31.8 ± 2.6 30.8 ± 2.3 28.8 ± 2.4 B,C
AA, C20:4 ω-6 9.5 ± 2.1 9.3 ± 1.4 8.5 ± 0.6 C
GLA; C20:3 ω-6 1.5 ± 0.3 1.4 ± 0.3 1.0 ± 0.3 B,C
C18:1 20.6 ± 3.0 18.0 ± 2.0 A 16.1 ± 1.4 B,C
C20:1 0.17 ± 0.05 0.18 ± 0.06 0.25 ± 0.07 B,C
FFQ
Total seafood intake (g/d) 34 ± 20 51 ± 35 75 ± 92
Periodontal data
PD (mm) 2.7 ± 0.3 2.8 ± 0.4 2.5 ± 0.3 C
CAL (mm) 2.9 ± 0.6 3.1 ± 0.9 2.8 ± 0.3
BoP (% of sites) 37 ± 15 31 ± 16 24 ± 14
PI (% of sites) 38 ± 10 32 ± 18 32 ± 13
RA data
RA duration, y 13 ± 8 14 ± 11 17 ± 15
DAS28 (score) 3.2 ± 0.9 2.9 ± 1.2 3.2 ± 1.1
VAS (score) 47 ± 15 27 ± 21 A 20 ± 15 B
MHAQ (score) 0.60 ± 0.41 0.35 ± 0.39 0.31 ± 0.23
Laboratory data
ESR (mm/h) 14 ± 13 19 ± 16 28 ± 15 C
CRP (mg/L) 5 ± 10 10 ± 15 6 ± 6
s-25(OH)D (nmol/L) 65 ± 25 75 ± 19 74 ± 16
AA, arachidonic acid; BoP, bleeding on probing; CAL, clinical attachment level;
CRP, C-reactive protein; DAS28, disease activity score; ESR, erythrocyte sedimen-
tation rate; FA, fatty acid; FFQ, food frequency questionnaire; GLA, gamma-
linolenic acid; MHAQ, modiﬁed health assessment questionnaire; PD, probing
depth; PI, plaque index; RA, rheumatoid arthritis; s-25(OH)D, 25-hydroxyvitamin
D; VAS, visual analog scale; wt%, weight percentage of total FA.
Values reported as mean ± standard deviation. Analyzed with Student t test and
Wilcoxon rank-sum. Letters in superscript (A, B, and C) denote a signiﬁcant dif-
ference (P < 0.05) between the ω-3 index groups: A ω-3 index <4 versus ω-3 index
4- ≤ 8; B ω-3 index <4 versus ω-3 index >8; C ω-3 index 4 to ≤8 versus ω-3 index
>8.
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Seafood consumption was found at a high frequency in this
group of RA patients. This ﬁnding may be explained by a long
tradition of Norwegian seafood consumption. However, seafood
consumption in complete fulﬁlment of the Nordic nutrition rec-
ommendations (NNR) [36] was found in only 35% of the patients.
Comparing our data with sex speciﬁc data from the latest na-
tional dietary survey (Norkost3) [37], we found that daily ﬁsh
consumption was 1.4 times higher in male RA patients com-
pared with females.
Females eating seafood at recommended frequency had better
health assessment (MHAQ and VAS) compared with females
eating less seafood. This is in line with a previous study on ﬁsh
consumption in RA patients, where signiﬁcantly lower disease
activity (DAS28) was observed in subjects consuming ﬁsh ≥2
times/wk compared to never or <1 time/mo ﬁsh intake [51].
The use of a validated FFQ questionnaire to estimate seafood
intake is a strength of this study. As a limitation, the FFQ is not
applicable to calculate ω-3 supplement intake.
The ω-3 index is originally considered a risk stratiﬁcation tool
for sudden cardiac death and has been used as a surrogate for
assessing tissue levels of EPA plus DHA [12]. An ω-3 index >8 has
been considered as favorable, and an index of <4 may be re-
garded as undesirable [42]. Oily ﬁsh and ﬁsh oil supplement are
the primary source of EPA and DHA. Dose-response studies
showed increasing levels of ω-3 PUFA by increasing amount of
ﬁsh oil supplementation in a dose dependent manner [12]. In this
study, all patients having an ω-3 index >8 were identiﬁed as ω-3
supplement users, and of them 83% had a seafood consumption
in accordance with NNR. Comparing our data with a study on FA
composition and presence of acute coronary syndrome in the US,
a group of Caucasian control patients showed an average 1.2 to
1.4 lower ω-3 index [52]. These results may reﬂect the sparse ﬁsh
intake in the typical American diet. In Japan, a country with a
strong tradition of ﬁsh consumption and low prevalence of car-
diovascular diseases, in older Japanese, an average ω-3 index
between 8 and 10 was reported [53]. These ﬁndings are in ac-
cordance with the data from our study, where the mean age was
highest for those with an ω-3 index >8 and the ω-3 index, ranging
from 9 to 13, was even higher than in the Japanese group. We
found that an ω-3 index >8 was related to more desirable patient
global health assessment (VAS) and periodontal conditions com-
pared with a lower ω-3 index. This ω-3 group consisted of ω-3
supplement users, exclusively. Our ﬁndings are consistent with
data of a prospective, randomized trial on ﬁsh oil supplemen-
tation that showed decreased VAS and DAS28 compared with no
supplementation [54].
Another strength of this study is the performance of FA anal-
ysis in whole-blood because the estimation of EPA and DHA intake
from seafood and/or ω-3 supplement is thought to be diﬃcult
due to differences in EPA and DHA content depending on season,
the ﬁsh’s diet, and food preparation methods [52]. Convention-
ally, FAs were measured in plasma or serum reﬂecting short-
term fat intake or in red blood cells (RBCs) reﬂecting long-term
fat intake. Whole-blood contains FAs from all lipid classes and
reﬂects FA status [55]. The EPA and DHA content of whole-
blood samples, which is used to calculate the ω-3 index, was found
to be highly correlated with that of RBC [42].
According to the Norkost3 study, the VitD3 supplement intake
was 6.7 μg/d in males and 4.9 μg/d in females [37]. In our study,
the mean VitD3 supplement intake was higher in females com-
paredwithmales and higher comparedwith sex speciﬁc data from
Norkost3. Compared with the reference values for recom-
mended intake of VitD3 supplement, the intake in patients <75
y in our study was twice as high in males and almost three times
higher in females [36]. Calcium supplementation containing VitD3
as a prophylactic adjuvant against osteoporosis in glucocorti-
coid treatment and intake of ω-3 supplement may reasonably
explain the higher intake in this patient group.
Assessing VitD status by measuring circulating s-25(OH)D is
generally considered as the best single marker of VitD status [40].
Currently, no general consensus on the required s-25(OH)D for
an adequate VitD status has been established. Some research in-
dicates that s-25(OH)D should be >50 nmol/L [41], but other
evidence suggests s-25(OH)D levels >75 nmol/L to cover both the
skeletal and non-skeletal beneﬁts of VitD [56].
VitD status is reported to be higher in Northern Europe com-
paredwith Southern Europe, despite higher latitude having shorter
periods of ultraviolet radiation from sun exposure [57]. Accord-
ingly, in the present study 88% had an VitD status within the
recommended range and approximately half of them had
s-25(OH)D level of ≥75 nmol/L. Norway’s coastal location with
strong tradition of fatty ﬁsh and cod liver oil consumption may
explain these ﬁndings. An inverse association between s-25(OH)D
concentrations and RA disease activity and severity has been re-
ported [19], but this was not seen in the present study. The overall
good VitD status in this group of RA patients may explain the in-
ability to show differences for RA disease activity and periodontal
diagnosis. Less intake of oily ﬁsh and lower/no VitD3 supple-
mentation was associated with lower VitD levels.
There are some limitations to the present study. The high per-
centage of low RA disease activity/remission and low prevalence
of deep periodontal pockets seen here may be the result of en-
rollment taking place among patients attending a rheumatologic
outpatient clinic at a university hospital with a treat-to-target
treatment regime and good access to synthetic and biological
DMARDs. Furthermore, over the last 40 y, a continuous improve-
ment in oral health was seen, with increased number of
individuals with no marginal bone loss and a decrease in the
number of subjects with moderate alveolar bone loss [45]. Good
systematic dental care, reﬂected by a high attendance rate and
frequency of dental recall visits as well as a high degree of self-
performed oral hygiene procedures may explain the overall low
severity of periodontitis (results not shown). On the other hand,
the perceived ability to pass through the examinations may have
inﬂuenced the patient’s decision to participate in the study and
may have resulted in refusal by patients with more severe RA
disease. The RA disease treatment mode with synthetic and/or
biological DMARDs showed large interindividual differences re-
sulting in subgroups with few patients. The limited interindividual
differences in outcome measurement of RA disease and peri-
odontal disease, in addition to subgroups with small numbers of
patients, could be responsible for the inability to detect signif-
icant differences. The patient recruitment from urban catchment
implies good access to medical care as well as the earlier men-
tioned participation bias may challenge the validity and
generalizability of the results. Therefore, the results of this study
should be evaluated with caution due to the small sample size
in the resulting groups.
Conclusions
In this group of RA patients, the overall range of RA disease
activity was low, with a high percentage of patients in remis-
sion. Despite this, periodontitis was more prevalent and severe
in RA patients and showed demographic and RA disease specif-
ic differences compared with what has previously been reported.
The prevalence of periodontitis was higher in seropositive versus
seronegative patients. The use of ω-3 supplement was related to
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a higher ω-3 index. An ω-3 index >8 was associated with better
RA disease outcome. In general, RA patients in this study had a
good VitD status, which may explain the inability to show dif-
ferences for RA disease activity and periodontal diagnosis related
to VitD.
A novelty of this study was the simultaneous assessment of
RA disease parameters, periodontitis measurements, marine ω-3
status by a FFQ and blood FA, and serum VitD levels in the same
group of patients. Longitudinal and interventional studies are
needed to further evaluate the effects of ω-3 and VitD3 on RA
and periodontitis.
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